These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1106 related items for PubMed ID: 19158438

  • 1. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
    Chiba Y, Onouchi T, Ikeda T, Adachi J, Tamura Y, Horiuchi T.
    Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
    [Abstract] [Full Text] [Related]

  • 2. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
    Nabipour I, Larijani B, Vahdat K, Assadi M, Jafari SM, Ahmadi E, Movahed A, Moradhaseli F, Sanjdideh Z, Obeidi N, Amiri Z.
    Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
    [Abstract] [Full Text] [Related]

  • 3. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.
    Kim JG, Kim JH, Lee DO, Kim H, Kim JY, Suh CS, Kim SH, Choi YM.
    Menopause; 2008; 15(2):357-62. PubMed ID: 17925661
    [Abstract] [Full Text] [Related]

  • 4. Receptor activator of NF(Kappa)B ligand/osteoprotegerin (RANKL/OPG) system and osteopontin (OPN) serum levels in a population of apulian postmenopausal women.
    D'Amore M, Fanelli M, D'Amore S, Fontana A, Minenna G.
    Panminerva Med; 2006 Dec; 48(4):215-21. PubMed ID: 17215793
    [Abstract] [Full Text] [Related]

  • 5. Differential bone metabolism between postmenopausal women with osteoarthritis and osteoporosis.
    Jiang LS, Zhang ZM, Jiang SD, Chen WH, Dai LY.
    J Bone Miner Res; 2008 Apr; 23(4):475-83. PubMed ID: 18052758
    [Abstract] [Full Text] [Related]

  • 6. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
    Kim JG, Kim JH, Kim JY, Ku SY, Jee BC, Suh CS, Kim SH, Choi YM.
    Menopause; 2007 Apr; 14(5):913-8. PubMed ID: 17667143
    [Abstract] [Full Text] [Related]

  • 7. Serum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study.
    Giusti M, Cecoli F, Fazzuoli L, De Franchis V, Ceresola E, Ferone D, Mussap M, Minuto F.
    Metabolism; 2007 May; 56(5):699-707. PubMed ID: 17445547
    [Abstract] [Full Text] [Related]

  • 8. Multiparameter analysis of serum levels of C-telopeptide crosslaps, bone-specific alkaline phosphatase, cathepsin K, osteoprotegerin and receptor activator of nuclear factor κB ligand in the diagnosis of osteoporosis.
    Piatek S, Adolf D, Wex T, Halangk W, Klose S, Westphal S, Amthauer H, Winckler S.
    Maturitas; 2013 Apr; 74(4):363-8. PubMed ID: 23391500
    [Abstract] [Full Text] [Related]

  • 9. The relationship between circulating osteoprotegerin levels and bone mineral metabolism in healthy women.
    Oh KW, Rhee EJ, Lee WY, Kim SW, Oh ES, Baek KH, Kang MI, Choi MG, Yoo HJ, Park SW.
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):244-9. PubMed ID: 15272921
    [Abstract] [Full Text] [Related]

  • 10. Changes in the serum sex steroids, IL-7 and RANKL-OPG system after bone marrow transplantation: influences on bone and mineral metabolism.
    Baek KH, Oh KW, Lee WY, Tae HJ, Rhee EJ, Han JH, Cha BY, Kim YJ, Lee KW, Son HY, Kang SK, Kim CC, Kang MI.
    Bone; 2006 Dec; 39(6):1352-60. PubMed ID: 16905375
    [Abstract] [Full Text] [Related]

  • 11. The RANKL/OPG system and bone mineral density in patients with chronic liver disease.
    Moschen AR, Kaser A, Stadlmann S, Millonig G, Kaser S, Mühllechner P, Habior A, Graziadei I, Vogel W, Tilg H.
    J Hepatol; 2005 Dec; 43(6):973-83. PubMed ID: 16143421
    [Abstract] [Full Text] [Related]

  • 12. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin in men with thyroid cancer.
    Mikosch P, Igerc I, Kudlacek S, Woloszczuk W, Gallowitsch HJ, Kresnik E, Stettner H, Grimm G, Lind P, Pietschmann P.
    Eur J Clin Invest; 2006 Aug; 36(8):566-73. PubMed ID: 16893379
    [Abstract] [Full Text] [Related]

  • 13. Relationships between serum osteoprotegerin, matrix metalloproteinase-2 levels and bone metabolism in postmenopausal women.
    Dai Y, Shen L.
    Chin Med J (Engl); 2007 Nov 20; 120(22):2017-21. PubMed ID: 18067789
    [Abstract] [Full Text] [Related]

  • 14. High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis.
    Ishii R, Morimoto A, Ikushima S, Sugimoto T, Asami K, Bessho F, Kudo K, Tsunematu Y, Fujimoto J, Imashuku S.
    Pediatr Blood Cancer; 2006 Aug 20; 47(2):194-9. PubMed ID: 16358318
    [Abstract] [Full Text] [Related]

  • 15. Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis.
    Reyes-García R, Muñoz-Torres M, García DF, Mezquita-Raya P, García Salcedo JA, de Dios Luna J.
    Menopause; 2010 Aug 20; 17(1):140-4. PubMed ID: 19574937
    [Abstract] [Full Text] [Related]

  • 16. RANKL/RANK/OPG system and bone status in females with anorexia nervosa.
    Ostrowska Z, Ziora K, Oświęcimska J, Swiętochowska E, Szapska B, Wołkowska-Pokrywa K, Dyduch A.
    Bone; 2012 Jan 20; 50(1):156-60. PubMed ID: 22001124
    [Abstract] [Full Text] [Related]

  • 17. The circulating concentration and ratio of total and high molecular weight adiponectin in post-menopausal women with and without osteoporosis and its association with body mass index and biochemical markers of bone metabolism.
    Sodi R, Hazell MJ, Durham BH, Rees C, Ranganath LR, Fraser WD.
    Clin Biochem; 2009 Sep 20; 42(13-14):1375-80. PubMed ID: 19523465
    [Abstract] [Full Text] [Related]

  • 18. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
    Mountzios G, Dimopoulos MA, Bamias A, Papadopoulos G, Kastritis E, Syrigos K, Pavlakis G, Terpos E.
    Acta Oncol; 2007 Sep 20; 46(2):221-9. PubMed ID: 17453373
    [Abstract] [Full Text] [Related]

  • 19. Serum osteoprotegerin levels in patients after liver transplantation and correlation to bone turnover, bone mineral density and fracture status.
    Fahrleitner A, Prenner G, Kniepeiss D, Iberer F, Tscheliessnigg KH, Piswanger-Sölkner C, Obermayer-Pietsch B, Leb G, Dobnig H.
    Wien Klin Wochenschr; 2002 Aug 30; 114(15-16):717-24. PubMed ID: 12602117
    [Abstract] [Full Text] [Related]

  • 20. The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone.
    Han KO, Choi JT, Choi HA, Moon IG, Yim CH, Park WK, Yoon HK, Han IK.
    Clin Endocrinol (Oxf); 2005 Mar 30; 62(3):349-53. PubMed ID: 15730418
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 56.